The DJJS prohibits the use of residents in programs for medical, pharmaceutical, or cosmetic experiments. (See exceptions below.) Under no circumstances is a stimulant, tranquilizer, or psychotropic drug administered for purposes of program management and control or for purposes of experimentation and research.

**Purpose**

The purpose of this policy is to establish the SYSC procedure regarding resident participation in research and drug testing.

**Procedure**

I. **Residents Involved in Clinical Drug Trial prior to Admission**
   
   A. DJJS recognizes that some residents who enter programs offered at SYSC may already be involved in a sanctioned clinical drug trial with the resident’s and their legal guardian’s permission and supervised by a personal physician. In those cases therapy may be continued under the direction of the SYSC physician if in agreement with the treatment. The Health Authority shall be notified in each case.

II. **Director Approval**

   A. SYSC physicians who determine that a resident requires individualized treatment with an investigational drug or procedure shall submit to the DJJS Director or designee, in writing, for authorization, the reason for the therapy and its possible risks and benefits. The physician shall also certify that non-investigational effective treatment is not available, shall obtain informed consent from the parent/legal guardian, and ensure that all FDA regulations and guidelines are followed throughout the course of the therapy. The DJJS Director or designee shall respond to each request within 2 business days.